Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin.
about
Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approachInflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation.Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients.SRSF1 facilitates cytosolic DNA-induced production of type I interferons recognized by RIG-I.Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease.Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation.Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway.Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis.mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target.Ribosomal protein s6-ps240 is expressed in lesional skin from patients with autoimmune skin blistering diseases.Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.Anandamide Suppresses Proinflammatory T Cell Responses In Vitro through Type-1 Cannabinoid Receptor-Mediated mTOR Inhibition in Human Keratinocytes.TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin.Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-α treatment.
P2860
Q28535430-5DE8084C-CC9B-4A9A-B3C6-C834BC83CDF8Q33897776-6B0499E7-8E63-4842-9A25-74C77555730CQ35156761-FEF88EF3-2E4F-40E7-85F8-4CA705A93274Q35556677-8F662107-ACAA-4DF9-87DB-1F334D52D1EBQ35922976-0F83926E-4C81-4D09-809E-B4612444E22BQ37649641-090266A5-F648-4FBA-B8B2-B3FDE8432B76Q38223953-2485193E-8446-4B34-A3A3-9FBBD57DC74BQ38779851-20382848-B224-48AD-B2D9-25E595F87975Q38841006-5447DE08-ED3E-4684-BE4F-2BA640FB8069Q39413456-F6C4C0CD-8768-4FB4-AA18-710FF5CC51B4Q41858959-315E4FF7-1563-4F69-88A5-57BE8ACDB16BQ42086185-B43BD89A-A014-4B4E-BA51-09A90233CBF6Q47133379-48DA16FC-4B4B-4BE0-8929-65FBA35C4375Q48326461-446A20EA-68B3-436F-B570-AA0E51710046Q48362769-4D8A0192-2796-4FAF-BD35-A9A9500E20BDQ52779156-F3C0190B-099E-420C-9317-75293F38768E
P2860
Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@en
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@nl
type
label
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@en
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@nl
prefLabel
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@en
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@nl
P2093
P2860
P356
P1476
Mammalian target of rapamycin ...... e activated in psoriatic skin.
@en
P2093
P2860
P304
P356
10.1111/BJD.12271
P407
P577
2013-07-01T00:00:00Z